8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                       OCTOBER 17, 2007 (APRIL 19, 2010)
                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)


                         COMPETITIVE TECHNOLOGIES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
                                    --------
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

                           1-8696          36-2664428
                           ------          ----------
         (COMMISSION FILE NUMBER)     (IRS EMPLOYER IDENTIFICATION NO.)


             1375 KINGS HIGHWAY EAST, FAIRFIELD, CONNECTICUT 06824
             -----------------------------------------------------
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

                                 (203) 368-6044
                                 --------------
              REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:

                777 COMMERCE DRIVE, FAIRFIELD, CONNECTICUT 06825
                ------------------------------------------------
         (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


                                 CTTC8k3411001

ITEM 1.01.  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On October 17, 2007, Competitive Technologies, Inc. (the "Company") entered into
an agreement with Daeyang E&C Co., Ltd., a South Korean corporation.  Under the
agreement, the Company granted Daeyang the right to manufacture the Company's
Calmare pain therapy device.  The term of the agreement is 10 years, and no
payment other than a $1,000 license fee was due under the agreement until units
are delivered.  Daeyang changed its name to GEOMC Co., Ltd. on March 29, 2008.

On August 22, 2008 the Company agreed to grant GEOMC the right to designate the
distributor of the Calmare device in South Korea, subject to the terms and
conditions of the October 17, 2007 agreement.

On January 18, 2010, the Company agreed with GEOMC to a memorandum of
understanding regarding per unit pricing of the Calmare pain therapy device.

On February 4, 2011, the Company agreed to grant GEOMC the right to designate
the distributor of the Calmare device in Japan, subject to the terms and
conditions of the October 17, 2007 agreement.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

The following exhibits are filed herewith:

No.  Description
---  -----------

10.1 License Agreement between Competitive Technologies, Inc. and Daeyand E&C
     Co., Ltd. (now GEOMC Co., Ltd.), dated September 25, 2007. Pursuant to Rule
     24b-2 of the Exchange Act, confidential information has been omitted and
     marked as "[Confidential Information Omitted]", and has been filed
     separately with the Securities and Exchange Commission pursuant to a
     Confidential Treatment Application filed with the Commission.

10.2 Distributor Appointment Agreement between Competitive Technologies, Inc.
     and GEOMC Co., Ltd. dated August 22, 2008 granting rights in South Korea.

10.3 Memorandum of understanding between Competitive Technologies, Inc. and
     GEOMC Co., Ltd. dated January 18, 2010. Pursuant to Rule 24b-2 of the
     Exchange Act, confidential information has been omitted and marked as
     "[Confidential Information Omitted]", and has been filed separately with
     the Securities and Exchange Commission pursuant to a Confidential Treatment
     Application filed with the Commission.

10.4 Distributor Appointment Agreement between Competitive Technologies, Inc.
     and GEOMC Co., Ltd. dated February 4, 2011 granting rights in Japan.

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                         COMPETITIVE TECHNOLOGIES, INC.
                                  (Registrant)

Dated: March 4, 2011                    By: /s/ Johnnie D. Johnson
                                        --------------------------
                                        Johnnie D. Johnson
                                        Chief Executive Officer

                                 CTTC8k3411002

EX-10.1

                                                                    Exhibit 10.1

                   TERRITORY EXCLUSIVE LICENSE AGREEMENT FOR
                             INTELLECTUAL PROPERTY

     AGREEMENT
     ---------

AGREEMENT EFFECTIVE as of September 25, 2007 "Effective Date") by mutual consent
of  Competitive Technologies, Inc., a Delaware corporation (hereinafter referred
to  as  "CTT")  a  company  having  a  place  of  business  at:

                         Competitive Technologies, Inc.
                                777 Commerce Dr.
                              Fairfield, CT  06825

and  Daeyang  E&C Co., Ltd., a South Korean corporation (hereinafter referred to
as  "DAEYANG"),  a  company  having  a  place  of  business  at:

                             Daeyang E&C Co., Ltd.
                              17F Samsung Fire B/D
                               1329, Seocho-2dong
                            Seocho-gu, Seoul, Korea


CTT  and DAEYANG being sometimes hereinafter referred to singularly as a "Party"
and  collectively  as  "Parties".


     WITNESSETH:
     ----------

WHEREAS, CTT has the rights to a patented device that treats drug-resistant pain
through  a  biophysical  rather  than a biochemical approach.  The non-invasive,
pain-free  treatment  is  by  means  of  a  multi-processor  device  able  to
simultaneously  treat  multiple  pain  areas  by  applying  single-use  surface
electrodes  to  the  skin.

WHEREAS,  CTT  has  the  exclusive  right to license these patents to others for
worldwide  markets;  and

WHEREAS,  DAEYANG  desires to obtain a license, in the Territory, from CTT under
the  Licensed Technology for the purposes of producing, the Licensed Product (as
hereinafter defined) during the term of this Agreement and market and distribute
the  Licensed  Product  in  Korea;  and

WHEREAS,  CTT  is  willing  to  grant DAEYANG a license, to produce the Licensed
Technology  in  accordance with the terms herein and market the Licensed Product
in  Korea.

NOW  THEREFORE,  in  consideration of these premises and of the mutual covenants

                                CTTC8K3411003

hereinafter  set  forth, CTT and DAEYANG mutually covenant and agree as follows:


ARTICLE  1.0  -  DEFINITIONS
----------------------------

For  the purpose of this Agreement, the following terms shall have the indicated
meanings:

1.1     The  term  "LICENSED  TECHNOLOGY"  shall  mean the intellectual property
listed  in  EXHIBIT  A.  (The  Pain  Management  Device)

1.2     The  term  "INVENTION" shall mean the invention as disclosed and claimed
in  the  Licensed  Technology  and  any  related  patents.

1.3     The  term  "CUSTOMER"  shall  mean an end-use customer of DAEYANG or its
Affiliate(s).  Internal  transfers,  or  other  internal  sales by DAEYANG to an
Affiliated  or  Related Interest are not Commercial Sales unless such Affiliated
or  Related  Interest  is  purchasing  Licensed  Product  in  an  arm's  length
transaction  at  market  price.

1.4     The  term "LICENSED PRODUCT(S)" shall mean any product sold to Customers
that  but  for the license granted hereunder, would infringe or otherwise embody
any  Licensed  Technology.

1.5     The  term  "NET SELLING PRICE" shall mean the actual gross selling price
of  each Licensed Product upon its Commercial Sale (as hereinafter defined), but
less  freight  out, royalty withholding taxes and export duty if included in the
gross price as routinely calculated by DAEYANG in its normal course of business.

1.6     The  term  "COMMERCIAL  SALE"  shall  mean  Licensed  Product  sold  to
Customers.

1.7     The  term  "AN  AFFILIATED  OR RELATED INTEREST" shall mean an entity in
which DAEYANG has a direct or indirect ownership interest of fifty percent (50%)
or  more,  or  any  entity  which directly or indirectly, or through one or more
intermediaries,  controls,  is  controlled  by,  or is under common control with
DAEYANG.

1.8     The  term  "TERRITORY"  shall  mean  Worldwide.

                                CTTC8K3411004


ARTICLE 2.0 - GRANT BY CTT
--------------------------

2.1     Subject  to  and  expressly conditioned upon the terms and conditions of
this  Agreement (including without limitation the royalty provisions hereof) and
to the rights that the United States Government may claim in and to any licensed
patent(s)  under  35  U.S.C.  200  et. seq., CTT agrees to grant and does hereby
grant  to  DAEYANG an exclusive license (the "License"), in the Territory, under
the  Licensed  Technology,  to  make and supply Licensed Product to CTT or CTT's
designated  customers.

2.2     The  License hereby granted by CTT does not include the right of DAEYANG
to  grant  any sublicenses except to an entity which is an Affiliated or Related
Interest.

2.3     The  License hereby granted by CTT does not include the right of DAEYANG
to transfer the License to another entity without prior written approval by CTT.

2.4     Absent  any event of default by DAEYANG, the License as to DAEYANG shall
terminate  in  accordance  with  the  termination  provisions  of  ARTICLE  5.0.

2.5     No  license  is  granted  by  CTT  to  DAEYANG,  either  directly  or by
implication,  estoppel  or  otherwise,  under  any patents or other intellectual
property  other  than  patents  that may be included in the Licensed Technology.


ARTICLE 3.0 - REMITTANCES UNDER THE LICENSE
-------------------------------------------

3.1     LICENSE  FEES.
        -------------

3.1.1     Upon  the  execution  of  this Agreement, DAEYANG shall remit to CTT a
nonrefundable  and  noncreditable  License fee of one thousand dollars ($1,000);
and,  within  thirty  (30) days of the execution of this License Agreement.  CTT
shall  provide  DAEYANG  the  License  Technology  in  Exhibit  A.

3.1.2     Within  two  hundred  forty  (240) days from the date of receiving all
manufacturing  information of the License Technology in Exhibit A, DAEYANG shall
produce  commercial  devices  with  the  Licensed  Technology.  CTT  may, at its
discretion,  extend  the  two hundred forty (240) day period up to an additional
ninety  (90)  days.  A License year will be measured from the date of commercial
production  ("License  Year").  in  South  Korea.


                                CTTC8K3411005

3.1.3     Payment  to  CTT  may  be  made  by  wire  transfer  as  follows:

BANK  NAME:               BANK  OF  AMERICA
BANK  ADDRESS:            ONE  LANDMARK  SQUARE
                          STAMFORD,  CT  06904
ABA  NUMBER:              [Confidential  Information  Omitted]
SWIFT  CODE:              [Confidential  Information  Omitted]
FOR  FURTHER  CREDIT  TO: COMPETITIVE  TECHNOLOGIES,  INC.
ACCOUNT  NUMBER:          [Confidential  Information  Omitted]

3.2     ROYALTY  RATE.  DAEYANG  and  CTT  will  share  profits of [Confidential
        -------------
Information  Omitted]% each from sales of Licensed Products produced by DAEYANG.

3.3     ROYALTIES  AFTER  TERMINATION.  In  addition  to  the foregoing, DAEYANG
        -----------------------------
agrees  to  pay  to  CTT  for  each Licensed Product sold after termination, but
produced,  manufactured or made and placed in inventory prior to termination, 5%
of  royalty  of  the  Net  Selling  Price  of  such  Licensed  Product.

ARTICLE 4.0 - ACCOUNTING PROVISIONS
-----------------------------------

4.1     Royalty  payments shall be computed on a monthly basis for each month of
each  calendar  year.

4.2     Payments  of  royalties  shall  be  made in United States Dollars within
thirty  (30)  days  following  the  end of each monthly royalty period, and such
payments  shall  include  all  royalties  that  have accrued during said monthly
period.

4.3     All  royalty  payments  made  hereunder shall be accompanied by a report
certified  by  an  officer  of  DAEYANG setting forth the quantity and prices of
Licensed Product sold by DAEYANG. Such report shall also be made if no royalties
are due in any such monthly period. The payments and reports shall be considered
confidential  to  DAEYANG  and shall not be disclosed to any third party without
written  consent  of  DAEYANG.

4.4     For  a  period  of  three  (3)  years  after  each  royalty  period  in
SUBPARAGRAPH  4.1,  DAEYANG shall keep records pertaining to such royalty period
in sufficient detail to permit the determination of royalties payable hereunder,
and  at  the request and expense of CTT upon no less than thirty (30) days prior
written  notice  will permit an independent Certified Public Accountant (CPA) or
its  Korean equivalent, selected by CTT and reasonably acceptable to DAEYANG, or
any  other person acceptable to both CTT and DAEYANG, to examine during ordinary
business  hours  once  in each calendar year such records as may be necessary to
verify  or determine royalties paid or payable under this Agreement. Such CPA or
other  person  shall report to CTT only the amount of royalties due and payable.
Such  examination  shall  be  at  CTT's  expense, unless the examination reports
underpayment in excess of five percent (5.0%) at which time said expense will be
borne  solely  by  DAEYANG.
--------------------------------------------------------------------------------
Confidential Treatment Requested by Competitive Technologies, Inc. Pursuant to
Rule 24b-2 of the Exchange Act.
--------------------------------------------------------------------------------

                                CTTC8K3411006


4.5     Upon termination or expiration of this Agreement for any reason, DAEYANG
shall  pay  to  CTT within sixty (60) days after such termination or expiration,
all  unpaid  royalties  accrued  prior  to  such  termination  or  expiration.


ARTICLE  5.0  -  TERMINATION
----------------------------

5.1     The  term  of  this  Agreement  shall  be  for  ten  (10) years from the
Effective  Date,  unless  earlier terminated as provided below. Thereafter, this
License  Agreement  will  be  automatically  renewed for subsequent one (1) year
terms  unless  earlier  terminated in accordance with the provisions established
herein;  or,  if  no less than ninety (90) days prior to the end of the ten (10)
year  period, or any subsequent renewal period thereafter, one Party informs the
other  of  its  desire  not  to  renew.

5.2     BANKRUPTCY

5.2.1     If  DAEYANG  shall  become  bankrupt  or  insolvent,  or  if DAEYANG's
business shall be placed in the hands of a receiver, assignee or trustee whether
by  the  voluntary  act  of  DAEYANG  or  otherwise, CTT shall have the right to
terminate this Agreement upon ten (10) days prior written notice to DAEYANG; and

5.2.2     If  CTT shall become bankrupt or insolvent, or if CTT's business shall
be  placed  in  the  hands  of  a  receiver, assignee or trustee, whether by the
voluntary  act of CTT or otherwise, DAEYANG may elect to retain its rights under
this  Agreement if the receiver, assignee, trustee or other entity so authorized
by  a  federal  bankruptcy  court  seeks to reject DAEYANG's License. If DAEYANG
elects  to  retain  its  rights, it shall not be subject to any claim seeking to
prevent  it  from  exercising its License rights, and the rights and remedies of
the  Parties  shall  continue  to  be  governed  by the terms of this Agreement.

5.3     If  DAEYANG  shall,  at  any  time,  be  in  substantial  default in any
obligation  under  this  Agreement, including but not limited to failing to make
any report, pay License fees, pay any royalties, or permit the inspection of its
books  and  records as hereinabove required, and such default shall not be cured
within  thirty (30) days after written notice from CTT to DAEYANG specifying the
nature  of the default, CTT shall have the right to terminate this Agreement and
the  License  granted  to  DAEYANG  hereunder by giving written second notice to
DAEYANG.

5.4     Any  termination  of this Agreement shall not relieve DAEYANG nor CTT of
any  obligation  or  liability  accrued  hereunder prior to such termination, or
rescind  or give rise to any right to rescind anything done or any payments made
or  other  considera-tion  given  hereunder  prior  to the time such termination
becomes  effective;  and  such  termination  shall not affect in any manner, any
right, or any remedy of either Party arising out of this Agreement prior to such
termination.

5.5     DAEYANG  may terminate this Agreement by giving notice to CTT in writing
at  least  sixty  (60)  days  prior  to  termination.

                                CTTC8K3411007


ARTICLE 6.0 - NOTICE
--------------------

6.1     Any  payment,  notice or other communication required or permitted to be
made  or  given  to  any  Party  hereto  pursuant  to  this  Agreement  shall be
sufficiently  made  or  given  on  the  date of mailing if sent to such Party by
certified  United States Postal Service Express Mail, or by utilizing an express
courier  service  (such as FedEx, UPS, DHL, etc.), addressed as set forth below,
or  to  such  other  address  as  the recipient shall have designated by written
notice  given  to  the  other  Party  as  follows:


                              IN THE CASE OF CTT:
                              ------------------

                                 Mr. Aris Despo
                 Executive Vice President, Business Development
                         Competitive Technologies, Inc.
                               777 Commerce Drive
                              Fairfield, CT  06825

                                WITH A COPY TO:
                                --------------

                                Mr. John B.Nano
                          Chairman, President and CEO
                         Competitive Technologies, Inc.
                               777 Commerce Drive
                              Fairfield, CT  06825

                     IN THE CASE OF DAEYANG E&C CO., LTD.:
                     ------------------------------------

                                Mr. Seung B. Oh
                            Executive Vice President
                             Daeyang E&C Co., Ltd.
                              17F Samsung Fire B/D
                               1329, Seocho-2dong
                            Seocho-gu, Seoul, Korea


                                WITH A COPY TO:
                                --------------

                               Ms. Young Hyun Lim
                            Chief Executive Officer
                             Daeyang E&C Co., Ltd.
                              17F Samsung Fire B/D
                              1329-3, SeoCho-2Dong
                            SeoCho-Gu, Seoul, Korea


                                CTTC8K3411008


ARTICLE 7.0 - TOOLING AND PRODUCTION
------------------------------------

7.1     TOOLING.     At  the termination of this License Agreement, CTT reserves
the  right  to  purchase from DAEYANG, or have destroyed by DAEYANG, all tooling
from  which  Licensed  Product  is  made.

7.2     MANUFACTURING.     The  manufacturing  facility  utilized by DAEYANG for
        -------------
the  production  of  Licensed  Product  will  be  ISO 13485:2003 certified. Such
certification  requires  the  implementation  and  maintenance  of  a  quality
management  system appropriate for the production, installation and servicing of
medical  device(s)  of  class  (I,  II,  III).


ARTICLE 8.0 - MISCELLANEOUS PROVISIONS
--------------------------------------

8.1     WARRANTY.  CTT  warrants  and  represents that it has the full right and
        --------
power  to enter into this Agreement and to grant the License granted herein, and
that  there  are  no  outstanding  agreements,  assignments,  or  encumbrances
inconsistent  with  the  provisions  of  this Agreement other than expressly set
forth herein and that no entity other than CTT has claimed any title or interest
to  the  Licensed  Technology.  CTT  makes  no other representation or warranty,
expressed  or implied, including warranty, guarantee or representation as to the
safety  and  efficacy  of the Inventions except as provided for herein, nor does
CTT  assume  any  liability  in  respect of any infringement of patents or other
rights  of  third  parties  due  to DAEYANG's operation under the License herein
granted.

8.2     INDEMNIFICATION.  DAEYANG  will  indemnify and hold harmless CTT against
        ---------------
any  and  all  actions, suits, claims, demands, prosecutions, liabilities, costs
and  expenses (including actual attorney's fees) based on or arising out of this
Agreement, including without limitation, the use, performance, and reliance upon
the  Licensed  Product,  or  the  use  of  the Licensed Patent by DAEYANG or its
Customers, and any representation made or warranty given by DAEYANG with respect
to  the results obtained by use of a Licensed Product. DAEYANG's indemnification
shall  not apply to any liability, damage, loss or expense to the extent that it
is  attributable  to  the grossly negligent activities, reckless, or intentional
misconduct  of  CTT.

8.3     ASSIGNMENT.  This Agreement, and the License herein granted shall not be
        ----------
assignable  by  DAEYANG  without  the  prior  written consent of CTT except that
DAEYANG  may  assign this Agreement and the License herein granted in connection
with  the  sale  and transfer of substantially all of DAEYANG's capital stock or
business  assets  relating  to  the  subject  matter  of  this  Agreement, or of
DAEYANG's  con-solidation  or  merger  with  another company; provided that such
assignee  shall assume, in writing, all of the obligations of DAEYANG hereunder.

                                CTTC8K3411009


8.4     COMPLIANCE.  DAEYANG  agrees  that  marketing  and  performance  of  the
        ----------
Licensed  Product, and Licensed Technology under this Agreement will comply with
all  applicable  Federal, state, and local laws, rules, regulations, and orders,
and  that it shall comply with all governmental requests regarding the efficacy,
safety,  and  marketing  of  the  Licensed  Product.

8.5     SEVERABILITY.  If any provision(s) of this Agreement shall be held to be
        ------------
invalid, illegal, or unenforceable, the validity, legality and enforceability of
the  remaining  provisions shall not in any way be affected or impaired thereby.

8.6     CONSTRUCTION.  This  Agreement  embodies the entire understanding of the
        ------------
Parties and supersedes any other agreement or understandings between the Parties
relating  to  the subject matter hereof. No waiver, amendment or modification of
this  Agreement  shall  be  valid  or  binding  upon such Parties unless made in
writing  and  signed  on  behalf  of  each  such  Party by its respective proper
officers  thereunto  duly  authorized.

8.7     EXECUTION.  This Agreement will not be binding upon the Parties until it
        ---------
has  been  signed  hereinbelow  by or on behalf of each Party, in which event it
shall  be  effective  on the Effective Date. No amendment or modification hereof
shall  be valid or binding upon the Parties unless made in writing and signed as
aforesaid.

8.8     HEADINGS,  NUMBER, AND GENDER.  The headings of the several sections are
        -----------------------------
inserted  for  convenience of reference only, and are not intended to be part of
or to affect the meaning or interpretation of this Agreement. In this Agreement,
where  the  context  so permits, the singular shall include the plural, and vice
versa,  and  references  to  a particular gender shall include the other gender.

8.9      NO  WAIVER.  Failure  by  any  Party  to  enforce any provision of this
        -----------
Agreement  or  assert  a claim on account of breach hereof shall not be deemed a
waiver  of  its  right  to enforce the same or any other provision hereof on the
occasion  of  a  subsequent  breach.

8.10      REMEDIES.  The  remedies  provided in this Agreement are not and shall
          --------
not  be  deemed  to  be exclusive and shall be in addition to any other remedies
which  any  Party  may  have  at  law  or  in  equity.

8.11       INDEPENDENT  CONTRACTORS.  The  Parties  hereto  are  independent
           ------------------------
contractors  and  are  not  and  shall  not  be  considered  as joint venturers,
partners, employers, or agents of each other and neither shall have the power to
bind  or  obligate  the  other  except  as  set  forth  in  this  Agreement.

                                 CTTC8K3411010


8.12       COUNTERPARTS.  This  Agreement  may  be  executed  in two (2) or more
           ------------
counterparts,  each  of  which  shall  be  deemed  an original, but all of which
together  shall  constitute  one  and  the  same  instrument.

8.13       FORCE MAJEURE.  None of the Parties hereto shall be liable in damages
           -------------
or  have  the  right  to  cancel  this  Agreement  for  any  delay or default in
performing hereunder if such delay or default is caused by conditions beyond its
control,  including  acts of God, government restrictions, war or insurrections.

8.14     PATENT  INFRINGEMENT.  DAEYANG  shall  promptly  inform  CTT  of  any
         ---------------------
suspected  infringement  of the Licensed Technology by a third party. CTT agrees
to  pursue  appropriate  action  against  any  such  third  party.

8.15     DISPUTES.  This  Agreement  is  governed by and construed in accordance
         --------
with  the  law  of  the  State of Connecticut and the United States, but without
regard  to  any  choice  of  law  provisions.  Any dispute, controversy or claim
arising  out of or relating to this Agreement (hereinafter collectively referred
to as "Dispute") shall be attempted to be settled by the Parties, in good faith,
by  submitting  each  such  Dispute  to  appropriate  senior management or legal
representatives  of  each  Party,  in  an effort to affect a mutually acceptable
resolution  thereof.  In  the  event  no  mutually acceptable resolution of such
Dispute  is  achieved  in  accordance with this subparagraph within a reasonable
period  of time, then either Party shall be entitled to seek final settlement of
such Dispute by any administrative or judicial mechanism which may be available.
Officers  of  the  Parties  having  the  rank  of vice president or higher shall
constitute  senior  management  under  this subparagraph. Any disputes hereunder
shall be resolved in the state or federal courts in Connecticut, and the Parties
hereby  consent  to  exclusive  jurisdiction  in  such  courts.

The  prevailing  Party  in any lawsuit brought for enforcement or breach of this
Agreement,  or  for infringement of the Licensed Technology shall be awarded its
attorney  fees  from  the  Party  so  charged.

8.16     PATENT  MATTERS.     CTT  shall  control  all  aspects  of  filing,
prosecuting and maintaining patents. CTT shall notify DAEYANG of the issuance of
any  patents  to  be  included  in  Licensed  Technology.

                                     *****

                                 CTTC8K3411011


IN  WITNESS  WHEREOF,  the Parties hereto have executed this Agreement as of the
Effective  Date  first  set  forth  above.

FOR     COMPETITIVE TECHNOLOGIES, INC.    FOR     DAEYANG E&C CO., LTD.

BY:     //S//                             BY:     //S//
        ------------------------------            ---------------------

NAME:   JOHN B. NANO                      NAME:   YOUNG H. LIM

TITLE:  CHAIRMAN, PRESIDENT AND CEO       TITLE:  PRESIDENT AND CEO

DATE:   10/17/07                          DATE:   10/17/07
        ------------------------------            ---------------------


































                                 CTTC8K3411012

EX-10.2

                                                                    Exhibit 10.2

                        DISTRIBUTOR APPOINTMENT IN KOREA


Pursuant to the Territory Exclusive License Agreement of the Pain Management
Device made October 17, 2007 between Competitive Technologies, Inc. (CIT) and
GEOMC, both parties agree that CTT delegates GEOMC to designate the exclusive
distributor for the Korea under the same conditions set forth in the Agreement.




Date: August 22, 2008


Competitive Technologies, Inc.               GEOMC


//s//                                        //s//
------------------------------               ----------------------------------
John B. Nano                                 Young Hyun Lim
Chairman, President & CEO                    President & CEO































                                 CTTC8K3411013

EX-10.3

                                                                    Exhibit 10.3

                          MEMORANDUM OF UNDERSTANDING


The following describes the understanding of both GEOMC Co. Ltd ("GEOMC") and
Competitive Technologies, Inc. ("CTT") regarding the revenue splits for sales of
Calmare Therapy MC-5A Unit.


1.  GEOMC  will receive $[Confidential Information Omitted] for the sale of each
unit.

2. Samples will be shipped at a cost of $[Confidential Information Omitted]/unit
and the cost will be shared equally between GEOMC and CTT.


These splits will be reviewed periodically and adjusted when appropriate.

//s//                           //s//
------------------------------  ---------------------------------
John B. Nano                    Young H. Lim
President & CEO                 President & CEO
Competitive Technologies, Inc.  GEOMC Co., Ltd.

1/14/10                         1/18/10
------------------------------  ---------------------------------
Date                            Date




















--------------------------------------------------------------------------------
Confidential Treatment Requested by Competitive Technologies, Inc. Pursuant to
Rule 24b-2 of the Exchange Act.
--------------------------------------------------------------------------------

                                 CTTC8K3411014

EX-10.4

                                                                    Exhibit 10.4

                        DISTRIBUTOR APPOINTMENT IN JAPAN


Pursuant to the Territory Exclusive License Agreement of the Pain Management
Device effective as of September 27, 2007 and executed on October 17, 2007
between Competitive Technologies, Inc. (CTTC) and GEOMC, Co. Ltd. (GEOMC)
(formerly known as Daeyang E & C Co., Ltd.), both parties agree that CTTC
delegates GEOMC to designate the exclusive distributor for Japan under the same
conditions set forth in the Agreement.



February 4, 2011

Competitive Technologies, Inc.               GEOMC Co., Ltd.



//s//                                        //s//
-------------------------------              ---------------------------------
Johnnie, J. Johnson                          Young Hyun Lim
Chief Executive Officer                      President & CEO






























                                 CTTC8K3411015